RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
Launched by NOVO NORDISK A/S · Nov 14, 2018
Trial Information
Current as of May 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent obtained before any study-related activities. Study-related activities are any procedures related to recording of data according to the protocol
- • The decision to initiate treatment with commercially available insulin Ryzodeg® has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study
- • Male or female, age more than or equal to 20 years (the legal age of adulthood) at the time of signing informed consent
- • Diagnosed with type 2 diabetes (T2D) for at least 26 weeks prior to signing informed consent
- • Available and documented glycosylated haemoglobin (HbA1c) value less than or equal to 12 weeks prior to initiation of Ryzodeg® treatment
- • For at least 26 weeks prior to initiation of Ryzodeg® treatment, one of the following must apply: A) Treated with insulin glargine (IGlar) (any formulation, including biosimilar IGlar). B) Treated with IGlar (any formulation, including biosimilar IGlar) and IGlar U300 for at least 12 weeks prior to initiation of Ryzodeg®
- Exclusion Criteria:
- • Previous participation in this study. Participation is defined as signed informed consent.
- • Pregnancy
- • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- • Hypersensitivity to Ryzodeg® or to any of the excipients
- • Previously treated with Ryzodeg®
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sapporo Shi, Hokkaido, , Japan
Kanagawa, , Japan
Tokyo, , Japan
Fukushima, , Japan
Chuo Ku, Tokyo, , Japan
Kanagawa, , Japan
Nagano, , Japan
Higashiosaka Shi, Osaka, , Japan
Hokkaido, , Japan
Tokyo, , Japan
Kawagoe Shi, Saitama, , Japan
Kawaguchi Shi, Saitama, , Japan
Kisarazu Shi, Chiba, , Japan
Sendai Shi, Miyagi, , Japan
Shimotsuke Shi, Tochigi, , Japan
Tochigi, , Japan
Fukuoka Shi, Fukuoka, , Japan
Arakawa Ku, Tokyo, , Japan
Hosu Gun, Ishikawa, , Japan
Kita Ku, Tokyo, , Japan
Saitama Shi, Saitama, , Japan
Shimotsuga Gun, Tochigi, , Japan
Shinjuku Ku, Tokyo, , Japan
Shizuoka City, Shizuoka, , Japan
Shizuoka Shi, Shizuoka, , Japan
Tsuchiura Shi,Ibaraki, , Japan
Yaizu Shi, Shizuoka, , Japan
Yokohama Shi, Kanagawa, , Japan
Patients applied
Trial Officials
Clinical Reporting Anchor and Disclosure (1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials